Obinutuzumab and Bendamustine Therapy - 28 day cycle. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Obinutuzumab and Bendamustine Therapy - 28 day cycle, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a riTUXimab-containing regimen.	1
Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies
HSE (2)	CD20 +	Follicular Lymphoma	Bendamustine, Obinutuzumab